Nyxoah SA Ordinary Shares (NYXH)
Nyxoah SA is a Belgian healthcare company specializing in innovative solutions for sleep-related disorders, particularly sleep apnea. The company develops neuromodulation devices designed to improve patient outcomes through minimally invasive procedures, focusing on innovative, patient-centric technologies for sleep disorder management.
Company News
Nyxoah received FDA Pre-Market Approval for its GENEO system to treat obstructive sleep apnea, launching a 50-person commercial team targeting high-volume U.S. implanting centers with 73.8% year-over-year revenue growth.
Nyxoah received FDA approval for its Genio® system to treat moderate to severe Obstructive Sleep Apnea, reporting Q2 2025 revenue of €1.3 million and facing a patent infringement lawsuit from Inspire Medical Systems.
CareCloud (CCLD) delivered earnings and revenue surprises of 93.75% and 2.22%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. Fastenal reported first-quarter FY24 sales growth of 1.9% Y/Y to $1.895 billion, missing the consensus of $1.914 billion. The company's first-quarter EPS was 52 cents, missing the consensus of 53 cents...